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Bronchiolitis obliterans syndrome (BOS) is a devastating complication after allogeneic stem cell trans-
plantation (allo-SCT). Early identiﬁcation of high-risk patients is pivotal for success. Lung proteins, KL-6, CCSP,
SP-A, and SP-D, measured in the serum may identify high-risk patients for BOS earlier than pulmonary
function tests (PFTs) can identify changes or clinical symptoms. Lung proteins were measured in patients’
serum at baseline and at 1, 3, 6, 9, 12, 18, and 24 months after transplantation along with history, clinical
examination, and PFTs. Serum levels of lung proteins were also measured in healthy control subjects. The
primary endpoint was the development of BOS conﬁrmed by pathological biopsy or National Institutes of
Health criteria. Between September 2009 and September 2011, 39 patients were enrolled. Six children
developed BOS at a median time of 200 days (range, 94 to 282). KL-6 levels were low in control subjects, at a
median of .1 U/mL (range, .1 to 1.5). Pre-SCT and 1-month KL-6 levels were signiﬁcantly higher in surviving
patients who developed BOS (n ¼ 6) versus those who did not (n ¼ 18) (pre-SCT: mean, 32.6 U/mL [IQR, 9.7 to
89.3] versus 5.8 U/mL [IQR, 2.1 to 12.6], P ¼ .03; at 1 month: mean, 52.5 U/mL [IQR, 20.2 to 121.3] versus 11.4
U/mL [IQR, 5.7 to 36.0], P ¼ .04). Three- and 6-month KL-6 levels continued to be higher in BOS group but
were not statistically signiﬁcant. CCSP, SP-A, and SP-D were not predictive. KL-6 measured in the serum of
children receiving allo-SCT may identify patients at high risk for the development of BOS. These patients will
beneﬁt from intensive surveillance protocol and early therapy before irreversible lung damage.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bronchiolitis obliterans syndrome (BOS) is a well-
recognized, noninfectious complication of stem cell trans-
plantation (SCT), with signiﬁcant morbidity and mortality
both in adults and children [1]. It is characterized by luminal
occlusion of the terminal and respiratory bronchioles caused
by inﬂammatory and ﬁbrous tissue formation. In severe and
advanced cases, the airway develops circumferential scarringedgments on page 1528.
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15.04.021with complete obliteration of the lumen, leading to the
clinical presentation of cough, shortness of breath, or
wheezing [2,3]. BOS usually occurs in the ﬁrst 2 years after
SCT [4] and leads to high risk of death, with mortality rates
reported between 13% and 100% in adults [5,6] and between
40% and 60% in children [7-9]. Diagnosis of BOS is a challenge
because clinical symptoms only occur after signiﬁcant
reduction in pulmonary function tests (PFTs); in severe cases,
irreversible lung damage has already occurred. Early detec-
tion is vital for successful stabilization of the disease with
immunosuppressant therapy before end-stage ﬁbrotic
changes and lung damage occur [10].
Understanding the pathogenesis of BOS is important to
help prevention, early detection, and treatment. Given that
BOS is commonly seen after lung transplantation as a form of
graft dysfunction caused by the host immune system
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mechanism, BOS after allo-SCT has similar pathogenesis.
However, it is the donor immune system rejecting the lungs
and other organs such as skin, gut, liver, or eyes in the host
presenting as graft-versus-host disease (GVHD) [11,12]. This
allo-immune phenomenon is supported by the fact that
development of symptoms of BOS after SCT usually occurs
around the time of immunosuppression withdrawal [13].
Withdrawal of immunosuppression therapy allows donor T
cells to undergo tissue-speciﬁc differentiation with
augmented cytokine responses enhancing the allo-immune
response [14]. This T cell inﬁltration, differentiation, and
cytokine release inwhat is seen as a “foreign organ,”which is
the host’s lungs, and leads to the ﬁbrotic environment in the
airways that contributes to the development of BOS [15]. IFN-
g and tumor necrosis factor (TNF)-a may play a factor in the
pathogenesis of BOS; however, these proteins are not lung
speciﬁc and are increased in the serum of patients with
GVHD with or without lung involvement [16].
Krebs Von Den Lungen-6 (KL-6) is a glycoprotein
expressed on pulmonary epithelial cells, and it is either un-
detectable in the serum of normal individuals or present in
very small amounts. Emerging evidence suggests that
epithelial cells of the proximal and distal air spaces release
host defense mediators that can facilitate the initiation part
of inﬂammatory airway changes; therefore, KL-6 has shown
to be a useful serum marker for BOS after lung trans-
plantation [17,18]. Other proteins that are commonly present
in the lungs are clara cell secretary protein (CCSP) and sur-
factant proteins A and D (SP-A and SP-D). Although these
proteins have been suggested as biomarkers for BOS after
lung transplantation [19,20], their diagnostic values are not
clearly established in the development of BOS post-SCT. We
hypothesized that KL-6, CCSP, SP-A, and SP-D when
measured in the serum of children receiving allo-SCT can
identify patients at high risk for the development of BOS
post-SCT earlier than PFT changes or the development of
clinical symptoms.
METHODS
Study Participants and Oversight
This prospective observational study was approved by the institutional
research ethics board at The Hospital for Sick Children (SickKids), and
informed consent/assent was obtained from parents and their children.
Children ages  18 years receiving allo-SCT at SickKids, Toronto from any
donor were eligible. We excluded children who received their post-SCT
follow-up care outside SickKids. A consenting participant (parent or child)
had to speak and understand English to be eligible for the study. Patients
who agreed to participate in the study had their demographic information
collected, including age, gender, diagnosis, donor source, conditioning
regimen, and GVHD prophylaxis. Blood samples for serum KL-6, CCSP, SP-A,
and SP-D; a detailed history and physical examination; and full PFTs were
obtained at the following 8 time points: before SCT (before the start of the
conditioning regimen) and 1, 3, 6, 9, 12, 18, and 24 months after SCT.
Conditioning Regimens, GVHD Prophylaxis, and Supportive Care
All patients were nursed in protective isolation in single rooms with
high-efﬁciency particulate air ﬁlters. All patients received ﬂuconazole for
fungal prophylaxis, ganciclovir for cytomegalovirus (CMV) pre-emptive
therapy based on weekly CMV PCR testing, or ganciclovir/high-dose
acyclovir prophylaxis in high risk-patients [21]. Pneumocystis jiroveci
pneumonia prophylaxis was given for at least 6 months after SCT.
For patients with GVHD, pneumococcal prophylaxis with penicillin
continued for at least 1 year after SCTor until vaccinatedwith pneumococcal
vaccine. Other prophylactic antibiotics and oral decontamination regimens
were not used. Fever during the neutropenic phase was treated with broad-
spectrum antibiotics and amphotericin B or caspofungin empirically for
prolonged fever and neutropenia.
Blood products were transfused to maintain hemoglobin concentration
> 70 mg/L and platelet counts of 20,000/mm3. CMV-negative patients weretransfused with CMV-negative blood products, and all blood products were
irradiated. Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive
days, after the neutrophil nadir, of absolute neutrophil counts > .5  109/L.
Primary graft failurewas deﬁned in patients surviving beyond dayþ28 (þ35
for cord stem cells) as failure to attain an absolute neutrophil count > .5 
109/L before death or receipt of a second graft. When busulfan was used as
part of the condition regimen, it was given intravenously with dose
adjustment based on area under the curve pharmacokinetic evaluation.
When total body irradiationwas used as part of the conditioning regimen, it
was given in 6 fractions of 200 cGy twice a day for 3 days (total 1200 cGy).
Standard GVHD prophylaxis was with cyclosporine A (CSA) and 4 doses
of methotrexate at 10mg/m2 given at daysþ1,þ3,þ6, andþ11 for unrelated
donors or related donors for a nonmalignant diagnosis or given at
day þ1, þ3, and þ6 for related donors with a malignant diagnosis. CSA and
methylprednisone (MP) at 2 mg/kg/day starting at day þ5 post-SCT was
given when using cord progenitor stem cells. Patients not tolerating CSA or
MP received tacrolimus instead of CSA and mycophenolate mofetil (MMF)
instead of MP. Acute GVHD grades II or more was treated. First-line GVHD
therapy was MP at 2 mg/kg/day divided into 2 doses per day given intra-
venously. For those patients already on 2mg/kg/day MP as part of the GVHD
prophylaxis, GVHD treatment was either an escalating MP dose to 30mg/kg/
day divided into 2 doses per day for 3 days or adding another agent such as
daclizumab. Response was deﬁned as the resolution of GVHD symptom-
atology with a stage 0 GVHD score based on the Glucksberg system [22].
Endpoints
The primary endpoint was the development of BOS based on histology
from lung biopsy or based on the National Institutes of Health consensus
criteria: absence of active infection, decreased forced expiratory volume in 1
second (FEV1) < 75% of predicted normal, and evidence of airway obstruc-
tion with a ratio of FEV1 to forced vital capacity < .7 [12].
Serum Biomarkers Analysis
Serum concentrations of KL-6, CCSP, SP-A, and SP-Dwere determined by
monoclonal antibodyebased commercial ELISA kits (BioVendor Research
and Diagnostic Products, Asheville, NC) by the Analytical Facility for Bioac-
tive Molecules of The Centre for the Study of Complex Childhood Diseases,
The Hospital for Sick Children, Toronto, Canada. The concentrations were
determined by comparing the A450 values with standard curves generated
using puriﬁed proteins. For these assays, aliquoted frozen samples were
thawed, clariﬁed, and serially diluted (1:5 to 1:10) before assay.
Statistical Analysis
Mean values in biomarker concentrations were compared using Student
t-test andWilcoxon-Mann-Whitney U test. A paired Student t-test was used
to determine the concentration changes in the same patient (pre-versus
post-SCT). For the baseline control comparison, KL-6 was measured at 1
time point only in healthy control subjects (siblings) at the time of their
blood work analysis for donor clearance.
RESULTS
Between September 2009 and September 2011, we
screened 82 children undergoing allo-SCT for eligibility.
Twenty-seven were excluded because they had their follow-
up elsewhere, 4 had language barriers, and 9 did not agree to
participate, leaving 42 children consenting for the study.
Three children withdrew from the study at 3, 6, and 12
months post-SCT, respectively, because of the long-distance
travel that was needed to attend the scheduled appoint-
ments. This resulted in a sample of 39 children in the study.
The characteristics of the patients are listed in Table 1.
Twenty-seven children received SCT for malignant disease
and 12 for nonmalignant disease. All patients withmalignant
diseases were in morphological remission before SCT.
Survival, Relapse of Malignant Disease, GVHD and
Transplant-Related Mortality
Two patients died before neutrophil engraftment, and 2
patients failed to engraft. The remaining patients engrafted
at amedian of 26 days post-SCT (range,12 to 67). At amedian
follow-up of 2.8 years (range, 2.1 to 4.2), 13 patients died, 4
due to leukemia relapse and 9 from transplant-related
complications. The course of 2 patients with engraftment
Table 1
Patient Demographics (N ¼ 39)
Characteristic Value
Male (%) 24 (61)
Median age at SCT, yr (range) 8.3 (1-17.2)
Age group < 6.99 yr (%) 11 (28)
Age group 7-18 yr (%) 28 (72)
Diagnosis (%)
AML 12 (31)*
ALL 9 (23)y
FA 5 (13)z
MDS 4 (11)
Thalassemia 3 (8)
Lymphoma 2 (5)x
SAA 2 (5)
CGD 1 (2)
WAS 1 (2)
Donor source
Related (%) 19 (49)
Unrelated (%) 20 (51)
Cord unrelated 12
Living unrelated 8
Conditioning regimen
Chemotherapy only (%) 28 (72)
Chemotherapy plus TBI (%) 11 (28)
GVHD prophylaxis
CSA plus MTX (%) 26 (67)
CSA plus other (%)k 13 (33)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leu-
kemia; FA, Fanconi anemia; MDS, myelodysplastic syndrome; SAA, severe
aplastic anemia; CGD, chronic granulomatous disease; WAS, Aiskott-
Aldrych syndrome; TBI, total body irradiation; MTX, methotrexate.
* Three patients with AML had BOS and none had clinical GVHD.
y One patient with ALL had BOS and multisystem severe GVHD (this pa-
tient has died).
z One patient with FA had BOS and no clinical GVHD.
x One patient with peripheral T cell lymphoma had BOS and liver GVHD.
k Other: mycophenolate mofetil or MP.
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varicella-zoster in another. They both received unrelated
cord stem cells and suffered primary engraftment failure.
Attempts for a salvage haploidentical SCT failed. Three pa-
tients died from acute pulmonary toxicity; in 1 of them, CMV
was recovered from bronchoalveolar lavage. One patient died
from multiorgan failure. One patient died from progressive
GVHDwith disseminated adenovirus infection, and 1 patient
died postoperatively while attempting to remove a large
urinary bladder carcinoma. The last patient died from severe
chronic GVHD with progressive BOS 11 months post-SCT.
In total, 6 patients developed BOS during the study. Four
were diagnosed based on National Institutes of Health
criteria and 2 based on lung biopsy. One patient who died
from severe chronic GVHD and BOSwas the only patient who
died in this group. The remaining 5 patients from the BOS
group were treated with multiple courses of high-dose ste-
roids and other immunosuppressants until their PFTs stabi-
lized. Among all survivors, 8 patients were treated for grades
II or more acute skin/gut GVHD. Six of the 8 patients did not
develop BOS.Development of BOS and Lung Proteins Levels
Six patients (3 with acute myelogenous leukemia, 1 with
acute lymphoblastic leukemia, 1 with peripheral T cell lym-
phoma, and 1 with Fanconi anemia) developed BOS at a
median time of 200 days (range, 94 to 282). All patients were
older than 7 years of age, and PFTs were performed at the
speciﬁed time points. Two patients had lung biopsies (pul-
monologist preference) reported as BOS. The other 4 patientshad FEV1 < 75% predicted, evidence of airway obstruction
with a ratio of FEV1 to forced vital capacity < .7 (.45, .66, .66,
and .67, respectively), and absence of active infection with
characteristic high-resolution computed tomography imag-
ing. These included air trapping, mosaic perfusion, bronchial
dilatation (bronchiectasis), and bronchial wall thickening
[23]. Only 2 of the 6 patients had clinical GVHD with BOS, 1
with liver GVHD and 1 with multisystem severe GVHD.
BOS patients had statistically signiﬁcant higher levels of
KL-6 compared with those who did not develop BOS at pre-
SCT and 1 month post-SCT (Figure 1). Levels of KL-6
remained higher at 3 and 6 months post-SCT in the BOS
group versus the non-BOS group but was not statistically
signiﬁcant. Figure 2 shows the 5 alive BOS patients and their
individual KL-6 levels over time post-SCT compared with
those alive patients who did not develop BOS. Interestingly,
when analyzing frozen samples for patients who died from
transplant-related mortality post-SCT, their KL-6 levels were
higher compared with the non-BOS group or healthy control
subjects; however, the difference did not reach statistical
signiﬁcance (Figure 1). Furthermore, CCSP, SP-A, and SP-D
levels were not predictive at any time point (data not
shown).
DISCUSSION
In this prospective study of children receiving allo-SCT,
we found that KL-6 measured in the serum at pre-SCT or at
1 month post-SCT can identify patients who are at high risk
for the future development of BOS. The high level of KL-6
pre-SCT in patients who later went on to develop BOS in-
dicates that these patients are predisposed to develop BOS
rather than BOS developing as a post-SCT complication.
KL-6 is a mucin-like glycoprotein expressed on pulmo-
nary epithelial cells. Circulating levels of KL-6 have diag-
nostic and prognostic signiﬁcance in a number of interstitial
lung diseases and when elevated are thought to indicate
disruption of the alveolar epithelial lining [24]. This disrup-
tion, along with potential SCT-related lung injury because of
chemotherapy and/or radiation, infections in the early post-
SCT period, and later donor lymphocytes inﬁltrating the
host’s lungs because of infections or as part of acute or
chronic GVHD, may together contribute to the sequence of
events leading to the damaging and ﬁbrotic result demon-
strated at BOS diagnosis. KL-6 as a serum biomarker has been
shown to be an important diagnostic and prognostic factor in
many pediatric and adult interstitial lung diseases, including
connective tissue diseases associated with interstitial lung
disease where there is auto-immunemediated inﬂammation
[25-28]. Lung inﬂammation post-SCT is somewhat similar;
however, it is an allo-immune rather than auto-immune
event.
The key to successful treatment of BOS post-SCT is early
diagnosis before signiﬁcant lung damage. Reduction in PFTs
is the mainstay for BOS diagnosis; however, a signiﬁcant
reduction occurs while the patient is completely asymp-
tomatic, and by the time the diagnosis is made based on PFT
reduction, signiﬁcant lung damage has already occurred [29].
Furthermore, young children are uncooperative or unable to
perform effective PFTs. Hence, KL-6 as a simple serum
biomarker can play a vital role in identifying asymptomatic
patients very early to initiate therapy early in the course of
the disease to improve the outcome.
Of note, in our study 5 of 6 patients with BOS are alive,
which, given the natural history of BOS, is very encouraging.
They all have abnormal but stable PFTs, and none of them at
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Figure 1. KL-6 concentrations in plasma of healthy control subjects and stem cell recipients at pre-SCT and at 1-month and 3-month post-SCT stages. (A) KL-6 is
virtually undetectable in healthy control subjects. All SCT patients had elevated concentrations of KL-6 in their plasma compared with healthy control subjects at all
time points (P < .01). Most patients who had elevated KL-6 either died or developed BOS. Patients who developed BOS had higher levels of KL-6 at the (A) pre-SCT
stage (P < .05) and (B) 1 month post-SCT (P < .04). (C) At 3 months post-SCT the differences were not signiﬁcantly different (P < .12). The variation in KL-6 at 3 months
was high, and 1 patient had already started receiving treatment for BOS. Lines mark median and interquartile ranges.
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patient died from BOS and severe multisystem GVHD despite
many immunosuppressant therapies. Although our study
was meant to be a “non-interventional” and focused on
serum biomarker values for BOS prediction, we believe the
structured regimen of thorough clinical examination and
frequent PFTs helped to establish a BOS diagnosis relatively
early, resulting in earlier intervention with high-dose ste-
roids that has led to this superior outcome. Furthermore,
only 2 of 6 patients with BOS had clinical GVHD, making
GVHD as a sole marker to identify high-risk patients for the
development of BOS not very useful.
The strengths of our study are its prospective design and
including a variety of patients with malignant andFigure 2. Individual patient KL-6 concentrations in the plasma in (A) alive non-BOS (n
not included. One patient (N) had not started therapy for BOS at time of data analys
starting therapy (downward arrows show time therapy started).nonmalignant diseases with different types of donors. The
structured protocol of regulated history taking, clinical ex-
amination, laboratory investigations, serum biomarkers at
multiple time points added more strength to our study.
Nonetheless, we acknowledge that 39 patients is a small
number, and we encourage testing KL-6 prediction for the
development of BOS after allo-SCT in larger studies. Although
it was not part of our study objective, those patients who
died post-SCT from transplant-related mortality had a trend
of high serum KL-6, and larger studies may be needed to help
us further understand the beneﬁt of KL-6 in identifying high-
risk patients for transplant-related mortality.
In summary, our study emphasizes the importance of KL-
6 levels in blood as a simple blood test performed pre-SCT¼ 18) and (B) alive BOS patients (n ¼ 5). One patient (D) died from BOS and was
is. Four patients with BOS showed reduction/stabilization of KL-6 levels after
A. Gassas et al. / Biol Blood Marrow Transplant 21 (2015) 1524e15311528and 1 month post-SCT as a mean to identify high-risk pa-
tients early in the BOS disease process. These patients will
beneﬁt from an aggressive pulmonary surveillance and early
therapy for a better outcome. Also, our study demonstrates
the importance of regular pulmonary-speciﬁc surveillance in
the ﬁrst 2 years post-SCT to prevent the severe and pro-
gressive form of BOS.
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